Why Compare Mounjaro and Wegovy Doses Before Choosing?
Understanding Mounjaro and Wegovy Doses: Mechanism Differences
When comparing Mounjaro and Wegovy doses, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural satiety hormones to reduce appetite and promote fullness after smaller meals. Mounjaro utilises tirzepatide, which activates both GIP and GLP-1 receptors, offering dual hormone pathway stimulation for weight management. This dual-agonist approach represents a different therapeutic strategy, though both medications work by influencing brain appetite centres and digestive processes.
The dosing implications of these mechanisms become apparent in clinical practice. Wegovy's GLP-1-only approach requires careful titration through five distinct dose levels over 16 weeks, whilst Mounjaro's dual-receptor activation follows a six-step escalation pattern with different milligram strengths. Both prescription-only medicines demand gradual dose increases to minimise gastrointestinal side effects, but the specific Mounjaro and Wegovy doses reflect their unique pharmacological profiles. Your prescriber will consider these mechanistic differences when recommending the most appropriate treatment pathway.
Mounjaro and Wegovy Doses: Comprehensive Pricing Comparison
EverydayMeds offers transparent pricing for both Mounjaro and Wegovy doses, allowing direct cost comparison throughout your treatment journey. Wegovy pricing begins at £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers benefit from the FIRST40 discount code at checkout, whilst returning customers can use DOSE25 to access these competitive prices. Our bundle options provide convenience rather than savings, with the Intro Duo (0.25mg and 0.5mg) priced at £169.99 for simplified ordering.
Mounjaro pricing follows a different structure reflecting its distinct dosing schedule, with six escalation points from 2.5mg through 15mg maintenance. Both medications require similar financial commitment over the initial titration period, though the maintenance phase costs vary between treatments. EverydayMeds' pricing model ensures you can compare Mounjaro and Wegovy doses fairly, with identical prescription fees and delivery charges applying to both options. Our 2-pen and 3-pen bundles offer Reliable Supply continuity, particularly valuable given periodic stock fluctuations affecting both treatments across UK pharmacies.
Clinical Evidence for Mounjaro and Wegovy Doses Effectiveness
The STEP clinical trial programme demonstrated Wegovy's efficacy across its five-dose escalation schedule, with patients achieving approximately 15% average weight loss at 68 weeks when using the full 2.4mg maintenance dose alongside diet and exercise modifications. The STEP 1 trial specifically validated the current Wegovy dosing protocol, showing superior results compared to placebo across all dose levels (Wilding et al., NEJM, 2021). These results established the evidence base for the specific Mounjaro and Wegovy doses now licensed by the MHRA for weight management in eligible adults.
Mounjaro's clinical development followed the SURMOUNT trial series, establishing efficacy for its six-dose escalation pattern through 15mg maximum dosing. Both medications demonstrated their effectiveness through rigorous Phase III programmes, though direct head-to-head comparison remains limited due to different trial designs and patient populations. The clinical evidence supports both dosing approaches when prescribed appropriately, with individual response varying based on factors your prescriber will assess during clinical evaluation.
How Wegovy Works Across Different Doses
Wegovy's semaglutide mechanism operates consistently across all dose levels, though efficacy increases with higher concentrations reaching GLP-1 receptors in appetite-controlling brain regions. The medication binds to GLP-1 receptors in the hypothalamus, reducing food cravings and promoting satiety signals that persist between meals. Each weekly injection delivers sustained semaglutide levels, with the 16-week dose escalation allowing tolerance development whilst progressively enhancing therapeutic effects. The final 2.4mg maintenance dose represents optimal receptor occupancy for most patients, though individual response to different Mounjaro and Wegovy doses varies considerably. This mechanism explains why gradual titration proves essential, as jumping directly to higher doses would likely cause intolerable gastrointestinal effects without allowing adaptation time.
Ordering Process for Mounjaro and Wegovy Doses
EverydayMeds streamlines access to both Mounjaro and Wegovy doses through our 3-minute online clinical assessment, designed to capture essential medical history and current medications that might influence prescriber decision-making. Our qualified prescribers review applications within standard 3 working days, with express 24-hour review available for urgent requirements. Once approved, both treatments ship via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements crucial for medication stability. The assessment process considers your BMI, previous weight management attempts, medical conditions, and preferences regarding injection frequency and storage requirements. Your prescriber may recommend starting with either medication based on individual factors, with option to switch treatments if initial response proves suboptimal after adequate trial period.
Storage and Practical Considerations for Mounjaro and Wegovy Doses
Storage requirements significantly differentiate Mounjaro and Wegovy doses in practical daily use, particularly for frequent travellers or those with limited refrigeration access. Wegovy FlexTouch pens maintain potency for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigerated storage at 2-8°C before first use, with identical once-weekly injection schedules simplifying routine adherence. The FlexTouch pen design used for Wegovy offers dose accuracy across all five strength levels, whilst Mounjaro utilises similar injection technology adapted for its six-dose range. This storage advantage makes Wegovy particularly suitable for patients with irregular schedules or limited consistent refrigeration access during travel periods.
Dose Escalation Strategies: Mounjaro and Wegovy Doses Compared
The escalation strategies for Mounjaro and Wegovy doses reflect careful balance between efficacy optimisation and tolerability management, though each follows distinct timelines suited to their pharmacological profiles. Wegovy's 16-week titration schedule allows 4 weeks adaptation at each dose level, providing sufficient time for gastrointestinal tolerance development whilst progressively enhancing appetite suppression effects. This gradual approach proves essential given semaglutide's potent GLP-1 receptor activation, which can cause significant nausea if increased too rapidly.
Mounjaro's six-dose escalation follows similar principles but accommodates tirzepatide's dual-receptor mechanism, which may require different adaptation periods for optimal tolerance. Both protocols prohibit dose-skipping, as this increases adverse event risk and may compromise treatment effectiveness. Your prescriber will monitor response at each escalation point, potentially extending time at lower Mounjaro and Wegovy doses if tolerance issues arise, ensuring treatment continuation rather than discontinuation due to preventable side effects.
Making Your Choice: Mounjaro and Wegovy Doses Decision Framework
Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber comprehensive flexibility in recommending the most appropriate treatment based on your individual circumstances and preferences. Our GPhC-registered pharmacy stocks both medications regularly, ensuring consistent supply regardless of which option proves most suitable for your weight management goals. The decision between these treatments involves multiple factors beyond simple dose comparison, including your medical history, lifestyle requirements, storage preferences, and previous experience with similar medications. EverydayMeds' clinical team provides ongoing support throughout your treatment journey, whether you begin with Wegovy's proven GLP-1 approach or Mounjaro's innovative dual-agonist mechanism. Your prescriber can help determine which option offers optimal benefit-risk balance for your specific situation, with option to reassess if treatment response suggests alternative approach might prove more effective.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
